Regeneron Acquires 23andMe to Advance Genetic Research and Drug Development

Regeneron Pharmaceuticals has agreed to acquire substantially all assets of 23andMe, the well-known DNA testing company, for $256 million. This acquisition includes 23andMe’s Total Health and Research Services business, as well as its extensive biobank of customer genetic data and samples.

Despite filing for bankruptcy earlier in the year, 23andMe will continue to offer its DNA testing services post-acquisition. The deal is subject to approval by the US Bankruptcy Court and includes commitments to comply with privacy laws and 23andMe’s own policies regarding customer data.

23andMe has amassed genetic samples and data from over 15 million customers since its inception. While customer data is anonymized and genetic samples are destroyed upon account deletion, the extent of retained information that will transfer to Regeneron remains unclear.

Regeneron’s co-founder George D. Yancopoulos highlighted that the acquisition will accelerate the company’s large-scale genetics research, aiming to develop new drugs and treatments based on genetic insights.

Once valued at $6 billion after going public in 2021, 23andMe struggled to turn a profit and filed for bankruptcy in March 2025. Its co-founder and former CEO, Anne Wojcicki, stepped down in conjunction with the bankruptcy filing.

Mark Jensen, chair of 23andMe, expressed optimism that the transaction maximizes business value while preserving customer privacy, choice, and consent regarding genetic data. He also noted that Regeneron has offered employment to all employees of the acquired units, ensuring continuity in the company’s mission.

Implications for Genetic Data and Drug Development

This acquisition underscores the growing importance of genetic data in pharmaceutical research. By integrating 23andMe’s vast genetic database, Regeneron can enhance its capabilities in precision medicine, tailoring treatments based on genetic profiles. However, it also raises critical questions about data privacy, consent, and ethical use of genetic information.

For consumers, the continuation of 23andMe’s services means ongoing access to personal genetic insights, but with new stewardship over their data. Transparency and robust privacy safeguards will be essential to maintain trust as this transition unfolds.

For the biotech and pharmaceutical industries, this deal highlights the strategic value of consumer genetic data and the potential to accelerate drug discovery through integrated data platforms. It also signals a trend toward consolidation where data-rich startups become key assets for larger pharmaceutical companies.